Although meningococcal disease caused by serogroup B remains an important public health concern, a licensed vaccine providing broad protection against this pathogen is not yet available. Advances in genomics have paved the way for the discovery of new vaccine candidates for inclusion into a multicomponent serogroup B vaccine. In this article, we will review recent advances in the development of these vaccines, focussing particularly on one of the 'next generation' MenB vaccines, 4CMenB.

Original publication

DOI

10.1586/erv.11.32

Type

Journal article

Journal

Expert Rev Vaccines

Publication Date

05/2011

Volume

10

Pages

575 - 588

Keywords

Antibodies, Bacterial, Antigens, Bacterial, Blood Bactericidal Activity, Cell-Derived Microparticles, Humans, Meningococcal Infections, Meningococcal Vaccines, Neisseria meningitidis, Serogroup B, Recombinant Proteins, Serum Bactericidal Antibody Assay